Scancell Holdings Plc
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Scancell Holdings plc (LSE:SCLP) is a clinical-stage biopharmaceutical company that develops novel immunotherapies targeting cancer through proprietary platforms including ImmunoBody and Moditope for vaccines; GlyMab and AvidiMab for monoclonal antibodies. ImmunoBody vaccines, such as SCIB1, iSCIB1+, SCIB2, SC129 and SC134, stimulate CD4 and CD8 T-cell responses against tumor-specific peptides to induce potent, durable anti-tumor immunity in solid tumors including metastatic melanoma; Moditope vaccines, such as Modi-1 and Modi-2, target citrullinated and homocitrullinated peptides to harness T-cell responses against a broad range of solid tumors; GlyMab antibodies, including SC2811 and SC27, enhance antibody-dependent cellular cytotoxicity by modifying glycan structures on monoclonal antibodies; AvidiMab enhances antibody potency through molecular modifications. The company, founded in 1996 and headquartered at Bellhouse Building, Oxford Science Park, Oxford, England, operates primarily in the United Kingdom with a pipeline focused on unmet needs in oncology across multiple solid tumor indications. Recent developments include a partnership with the NHS Cancer Vaccine Launchpad for fast-tracked access to SCOPE trials in melanoma patients; a strategic alliance with PharmaJet for the Stratis needle-free injectable device in iSCIB1+ studies; a second commercial license agreement with Genmab yielding $6 million upfront and potential milestones of $630 million plus royalties, validating the GlyMab platform; incorporation of GlyMab Therapeutics Limited as a wholly-owned subsidiary in June 2025; and accelerated plans for randomized registration studies of iSCIB1+ starting in 2026 following Phase 2 data.
Company News
Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial
Scancell (LON:SCLP) Share Price Crosses Below 200-Day Moving Average – Here’s Why
Scancell Holdings secures $25m financing as it advances melanoma trial
Cancer vaccine breakthrough at Moderna raises hopes for Scancell's melanoma programme
Marvell shares jump as Google warrant deepens AI chip partnership
Scancell secures UK clearance for late-stage melanoma trial
Ford and GM upgraded by Jefferies on improving outlooks, stronger cash generation
Chip stocks slide as China advances domestic lithography, memory production
Scancell sees high demand in retail share offer, seals £15.7m from UK investors
SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612
American Airlines shares fall as fuel costs weigh on third-quarter outlook despite earnings beat
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Scancell to join Nasdaq through Neuphoria merger and $89 million funding package
Scancell to join Nasdaq through Neuphoria merger and $89 million funding package
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Scancell confirms advanced talks over reverse merger with Neuphoria
Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up
Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up
Scancell wins FDA fast-track status for melanoma immunotherapy
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study